ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

14 links0 made here, not in the record27 judgments2 judges (the rules as one: Rule based)1 record change seen
Model not recordedRule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05482893Spevatamig (PT886) asMonotherapy or inCombination With Chemoand/or Targeted Therapyand/or ICI, for theTreatment of Patients WithAdvanced GastrointestinalPhanes TherapeuticsPhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 28 · ClinicalTrials.gov record · Version of 2026-09-28Version of 2026-09-28CONDITIONSBiliary Tract NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionColorectal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSINT017215Entry “Spevatamig (PT886)”, read by o…›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedPaclitaxelIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Abraxane”, read by our name ru…›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabEntry “KEYTRUDA® (pembrolizumab)”, re…›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundFolfox protocolEntry “FOLFOX”, read by our name rule›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundINT013509Entry “CAPOX”, read by our name rule›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundFolfirinoxIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundINT000593Entry “TAS 102”, read by our name rule›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinEntry “Gemcitabine Combined With Cisp…›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundINT012085Entry “NALIRIFOX”, read by our name r…›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

INT017215

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Spevatamig (PT886)”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 28The record itselfClinicalTrials.gov recordVersion of 2026-09-28Record change
Nov 1INT017215A model not recordedTestedCurrent
Nov 1PaclitaxelA model not recordedBackgroundCurrent
Nov 1GemcitabineA model not recordedBackgroundCurrent
Nov 1Albumin-Bound PaclitaxelA model not recordedBackgroundCurrent
Nov 1PembrolizumabA model not recordedBackgroundCurrent
Nov 1Folfox protocolA model not recordedBackgroundCurrent
Nov 1INT013509A model not recordedBackgroundCurrent
Nov 1FolfirinoxA model not recordedBackgroundCurrent
Nov 1INT000593A model not recordedBackgroundCurrent
Nov 1BevacizumabA model not recordedBackgroundCurrent
Nov 1CisplatinA model not recordedBackgroundCurrent
Nov 1INT012085A model not recordedBackgroundCurrent
Nov 14Biliary Tract NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Colorectal NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18INT017215Rule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18Folfox protocolRule based · role ruleBackgroundAgrees
Nov 18INT013509Rule based · role ruleBackgroundAgrees
Nov 18FolfirinoxRule based · role ruleBackgroundAgrees
Nov 18INT000593Rule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18INT012085Rule based · role ruleBackgroundAgrees
As of nowBiliary Tract NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.